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ABSTRACT
Phytochemicals found in food have revealed noteworthy roles in treating and managing a large number of human diseases. The
structure, source, bioavailability, pharmacokinetics and anti-cancer activity of resveratrol, a bioactive compound present mainly in red
wine, are reviewed in this article. Resveratrol, a polyphenol, is a stilbene-type aromatic phytoalexin, which is principally found in red
grapes. Numerous physiological activities like antioxidant, anticancer and antiaging activities of resveratrol have been elaborated in vitro,
in investigational animal models and in human subjects. Studies in humans are still in the preliminary phases and thus, more investigations
are required. The anticancer activity of resveratrol is essentially attributable to the genetic variation, moreover, the stimulation of apoptosis
through a number of modes, as well as expressions, all causing a reduction in tumor initiation, promotion and progression. No side effects
are produced by resveratrol, even when used at elevated quantities. Consequently, resveratrol holds excellent potential to be consumed as
an adjunctive or substitute remedy for cancer.
Key words: antioxidant, antiaging, anticancer, resveratrol, wine

INTRODUCTION
The relationship between diet and health is unavoidable because there are certain bioactive compounds in our
diet which inhibit the effects and risk of a large number
of diseases. When we talk about food, then wine seems to
play an essential part with its health promoting properties.
The association of health with wine is actually a “French
Paradox”, observed in the Mediterranean population. The
relationship between diet and death by cardiovascular
diseases was first studied and published by Renaud et al.(1).
Myocardial infarction rates were observed to be 40% less in
France than the rest of Europe because of proper consumption of wine aside from their diet which is rich in saturated
fats. The research on the health effects associated with wine
confirms that red wine as a dietary supplement enhances
antioxidant activity and reduces oxidative damage and
platelet aggregation. In the light of these research studies, it
can be suggested that moderate consumption of wine reduces
cardiovascular risks(2-6).
* Author for correspondence. Tel: 00923142082826;
Fax: 0092992383441; E-mail: gmdogar356@gmail.com
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Including a moderate amount of wine in diet can reduce
the risk of cancer, non-hodgkin’s lymphoma(7), adenocarcinoma of oesophagus(8-10) and gastric cardia(11). However,
some scientists did not find any relationship between wine
and the prevention of different health risks(12,13), while some
researchers found some negative effects as well(14).
Among wines, a higher percentage of antioxidants
(polyphenols) is present in red wines and the polyphenols
are actually released from the skin and seed of grape during
the wine-making process. Almost 1.8 g/L of antioxidants is
present in a bottle of red wine, compared to white wine, which
contains only 0.2-0.3 g/L of antioxidants(3). The polyphenolic
content present in wine depends only on the wine-making
process. In the synthesis of white wine, the fermentation is
carried out after removing the skin and seeds of the grapes,
so white wine contains lesser polyphenols. The antioxidant
properties of wines are directly related to the presence of
polyphenols. Therefore, white wines show about ten times
lesser effects than red wines in vitro(15). Apart from resveratrol, white wines contain other antioxidants like tyrosol
and hydroxycinnamic acid, but the overall health-promotion
activities are lesser than red wines. The studies have lead the
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research attentions to focus on phenolic contents and differentiate its effects than other non-alcoholic constituents(16-19).
The phenolic compounds in red wine also show potential
effects in cardiovascular problems and cancer, while experimenting on different animals. In addition, the feed of rats
have been supplemented with phenolic compounds, ethanol,
or both ethanol and polyphenols in order to differentiate their
effects on blood pressure and the heart. It was concluded from
these experiments that the polyphenolic extract is most effective in reducing cardiovascular risk(16). Clifford et al. proved
that de-alcoholized red wine as a supplement of proper diet
has positive effects on tumor onset in transgenic mice(17).
These effects are more pronounced due to the synergy among
different phenols: caffeic acid, resveratrol and catechin(18,19).
Apart from resveratrol, the low concentrations of other
phenols show very useful activities due to synergy, such as
the inhibition of oxidative stress.
A number of papers in the literature can be found in
which anticancer properties of resveratrol have been
studied(20-26). Research articles also elucidated the mechanisms that reduce cancer progression. These studies
provided evidence that resveratrol can be a promising
anti-carcinogenic compound, which exerts potential effects
at the initiation, promotion and progression stages of
carcinogenesis(21-24,27,28).
This review is focused on the anti-cancer activity of
resveratrol, present mainly in wine, along with its structure,
availability, pharmacokinetics and possible mechanism as an
anti-cancer agent.

LITERATURE SEARCH METHODOLOGY
A broad literature review in English was carried out,
employing electronic databases like Medline (1966-2011)
and EMBASE (1980-2011). Initially, a sample search was
made using terms like “resveratrol” and “activity” together.
After that, various terms like “in vitro” “antioxidant”, “antiaging” and “anticancer” were combined with “resveratrol”
and “activity” for an advanced search. The literature assessment was carried out by investigating the reference lists of
the choosen publications exhibiting innovative investigations to construct an assured review. The publications appropriate for inclusion were the in vitro studies presented in the
English language. All the literature chosen was corroborated
for doubling, which if detected were excluded.

RESULTS AND DISCUSSION
I. Chemistry and Dietary Sources of Resveratrol
Resveratrol (3,5,4´-trans-trihydroxy stilbene, Figure 1)
belongs to the stilbene family and was detected for the first
time in Vitis vinifera grapevines(29). It was synthesized in
1992 from leaf tissues by fungal infection or UV light(30).
Resveratrol is a lipophilic off-white powder that is soluble
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Figure 1. Chemical structure of trans-resveratrol.

in ethanol (50 mg/mL) and DMSO (16 mg/mL). Its melting
point range is 253-255°C. Its molecular formula and weight
are C14H12O3 and 228.25 g/mol, respectively(31). Due to its
poor water solubility and high membrane permeability, it can
be classified as a Biopharmaceutical Classification System
class-II drug(32,33).
Resveratrol exists in both the cis- and trans-isomeric
forms, where cis-resveratrol relatively exists in a larger
amount than the trans-isomer in Italian red wines(34). Resveratrol consists of two aromatic rings bridged by ethylene and
the carbon atoms of aromatic ring are further attached to
three hydroxyl groups. Due to the ethylene group between
the aromatic groups, resveratrol exists in cis- and transisomers, and the glucoside derivative of resveratrol is known
as piceid. The hydroxyl group of the trans-isomer at positions
3 and 4 are very important as it shows antioxidant and apoptotic activities(35). Resveratrol and other compounds of the
stillbene family are present in many plants. We can also get
resveratrol from different foods such as grapes, different nuts,
berries, dark chocolate and red wine. Among these sources,
red wine contains the highest percentage of resveratrol(36).
The concentration of resveratrol is higher in red wine than
white wine, because it is present in skin and seeds of grapes,
which comes in contact during the fermentation process while
making red wine. Due to this reason, the resveratrol concentration in rose wine (0.41 mg/L) is in between red (1.90 mg/L)
and white wines (0.13 mg/L)(37-40). The level of resveratrol
in different brands of wine depends on the different varieties
of grapes. It also depends on the geographical and environmental conditions. It has been observed in different brands
of Italian white wines that the concentration of resveratrol
is even lower than the quantification limit(41). Trebbiano
white wine and Sangiovese red wine contain 0.19 mg/L and
0.26 mg/L of resveratrol, respectively(42). Thus, the level
of resveratrol in different commercial red and white wines
depends mainly on the wine-making process, and its concentration can be increased by extracting mainly from the skin
of grapes(43,44). However, its exact concentration cannot
be predicted in advance because a large number of factors
are involved that affects resveratrol synthesis and different
concentration ranges have been described in literature(45,46).
The concentration of trans-resveratrol content in different
foods is shown in Table 1.
In plants, resveratrol is synthesized from phenylalanine
and malonyl-CoA(47). The reaction is catalyzed by three
key enzymes and follows the shikimic pathway: phenylalanine ammonium lyase, coenzyme A ligase and stilbene
synthase (Figure 2). As the production of these enzymes can
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be enhanced by stress(48), the percentage of resveratrol can
be increased after exposure to biotic or abiotic stress and
microbial attack, which will ultimately enhance the defence
mechanism of plants because resveratrol is known to be a
phytoalexin(49). The different forms of phytoalexins depend
on the plant sources. The structural forms of phytoalexins are
named as hydroxamic acids, di, or sesqui-terpenoids, isoflavonoids, acetylenes, indole alkaloids and stilbenes(50). The
bioactivity of resveratrol in animals is related to its phytoalexinic properties in plants. The percentage of resveratrol in
grapes and ultimately in wine depends on several factors such
as stress exposure, pathogenic attack(51,52), postharvest treatments with chitosan(53,54) and UVC(55). The use of transgenic
yeast can also increase the level of resveratrol in wines(56).
Such treatments are applied to enhance the level of resveratrol in wine and to ensure the constant and high percentage
of this compound over the years, which is highly important
according to the commercial point of view to attract the
consumers by exploiting nutritional and health terms(58).
Aside from trans-resveratrol, other compounds of the
stilbene family such as piceid, viniferin and pterostilbene
are also present in grapevine leaves as well as in wines
prepared from these sources(59-63). As the percentages
of other compounds of stilbene family are very low when

Table 1. Representative examples of some foods as a source of
trans-resveratrol
Concentration of
trans-resveratrol

Reference

0.5 µg/g

Bums et al.(11)

Red wine

53 - 1057 µg/100 mL

Bums et al.(11)

White wine

0.05 - 1.8 µg/100 mL

Sobolev and Cole(12)

Peanuts (Boiled)

5.1 µg/g

Bums et al.(11)

Peanuts butter

0.3 µg/g

Bums et al.(11)

0.018 - 15 µg/g

Sobolev and Cole(12)

Food
Black grapes

Peanuts products
(Commercial)

compared with resveratrol, there are not many reports on
their bioactivities. Stilbene derivatives are also formed from
trans-resveratrol by different reactions. In susceptile grapevines, resveratrol is produced initially and readily converted
to piceid, whereas in resistant varieties, it changes into toxic
viniferins by toxic conditions(64).
II. Bioavailability and Pharmacokinetics of Resveratrol
Many studies on the bioavailability of resveratrol
in humans and animals (particularly in mice) are available
in literature(65-68). Approximately 70% absorption of orally
ingested resveratrol is reported(66). The high bioavailability
of lipophilic resveratrol is perceived on concomitant administration with a fatty diet, but no effect on its bioavailability
in humans has been observed. Vitaglione et al. administered
resveratrol in the form of red wine with meals containing
different quantities of fats(69). In addition, Van Ginkel et al.
reported that in spite of its low bioavailability, this phytochemical showed cytotoxicity in rats even though there was
no detectable concentration of resveratrol in tumor tissues(70).
Due to strong affinity between resveratrol and albumin,
an improved distribution and bioavailability of circulating
resveratrol has been observed(71). After oral administration
in rats, 3H-labelled trans-resveratrol was distributed in the
liver, lungs, heart and brain(72). After ingestion of 4 mL of
red wine (each liter of red wine contained 6.5 mg of resveratrol) for 15 days in rats, this phytochemical was found to be
distributed in the plasma, bile, feces and urine, as well as in
the heart, stomach, intestine, liver and kidneys(73-76). Similar
bioavailability was observed in another study conducted in ten
healthy human volunteers, who ingested 300 mL of red wine
for 15 days(3). In contrast, a very low plasma resveratrol level
was observed after the intake of 300 mL of white wine for
15 days in another group of ten healthy human volunteers(3).
Walle et al. described the liver metabolism of resveratrol
and narrated that its phase I metabolism did not occur due
to the absence of the required enzymes(77); however, phase

OH
HO
HO
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NH2

O
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Figure 2. Biosynthesis of trans-resveratrol.
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II metabolism of resveratrol took place and resulted in its
sulfate and glucuronide metabolites(65-68). Dihydroresveratrol is the metabolite that is produced by the micro-flora of
the gastrointestinal tract. After oral administration, the time to
reach maximum plasma concentration and half life for resveratrol metabolites is about 30 min and 9.2 h, respectively(77).
The dose of ingested resveratrol affects the plasma levels of
resveratrol and its metabolites(78). After the moderate use of
red wine with an identified concentration of resveratrol, five
different metabolites including resveratrol monosulphate,
dihydroresveratrol monosulphate, dihydroresveratrol and
two isomeric forms of resveratrol monoglucuronide were
found in the urine samples of volunteers(79). Six different
metabolites, namely trans-resveratrol-3-O-glucuronide, cisresveratrol-3-O-glucuronide, cis-resveratrol-3-O-glucoside,
free trans-resveratrol, resveratrol-40-O-glucuronide and
trans-resveratrol-4-O-glucoside, are found in low density
lipoprotein samples after the consumption of 250 mL of red
wine(80). Additional experimental data for the therapeutic
nature of the metabolites is needed to be investigated due
to the elevated level in vivo of each metabolite from orally
administered resveratrol, compared to resveratrol itself.
Resveratrol and its metabolites are discharged via urine and
feces(68).
Chen et al. observed a dose-dependent response of
resveratrol(81). Bertelli proved that resveratrol was effective
in cancer and cardiovascular disease in a dose of 5-100 mM
and 100 nM - 1 mM, respectively (in vitro trials)(82), which
also explained how a relatively low dose of resveratrol
attained from red wine or other dietary sources could provide
therapeutic effect(83). Bertelli also recommended that the long
term intake of red wine in an average amount could result in
the absorption of resveratrol in an adequate amount to yield
valuable outcomes on human health(82).
Mertens-Talcott and Percival elaborated the potential
interactions between resveratrol and other dietary constituents, such as the synergestic effect of resveratrol with both
quercetin and ellagic acid for the stimulation of apoptotic
cascade in human leukemia cells(84), with ethanol in the
under-expression of iNOS(85), with vitamin E in the avoidance of lipid peroxidation(86), with catechin in the defense
of PC12 cells against b-amyloid toxicity(87), with nucleoside
analogues in the inhibition of HIV1 replication in cultured
T lymphocytes(88), and with tyrosol and b-sitoesterol in
modulation of LDL oxidative stress and PGE2 synthesis(89).
Goldberg et al. investigated the absorptive efficiency, after
oral administration to healthy human volunteers, of transresveratrol, catechin and quercetin in 3 matrices, namely
white wine, grape juice and vegetable homogenate(90). An
equivalent absorption of these 3 polyphenols in the different
media was observed. De Santi et al. reported that quercetin,
an essential constituent of red wine, increased the bioavailability of unconjugated resveratrol by inhibiting the sulfation
of resveratrol in both the liver and duodenum(76).
Different studies have been carried out to determine
resveratrol toxicity. No side effect, even in high dose, has
been reported. However, extremely high doses may cause
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some adverse effects. After the intake for 28 days of resveratrol equivalent to thousand-folds the content in red wine,
Juan et al. observed no side effects in rats(91). Williams et al.
also observed similar outcomes in a 28-day study conducted
on rats, where Resvida™ (high purity resveratrol content)
produced no side effects at 50, 150 and 500 mg per kg
body weight per day(92). Likewise, in a 90-day study in rats,
Resvida™ caused no side effects at the largest tested dose,
700 mg per kg body weight per day.
III. Antioxidant Property of Resveratrol
Reactive oxygen intermediates are normally produced
in the body by metabolic activities and these substances are
removed by the process called detoxification, in which intracellular enzymes like glutathione, catalase, and superoxide
dismutase play its role. If they are not removed, abnormal
accumulation of oxygen intermediates occurs, resulting in
“oxidative stress”. In this condition, oxygen intermediates
react with biomolecules and cause harmful effects to the
body(93), such as the narrowing of blood vessels and heart
attack(94).
However, these adverse effects can be circumvented
by the antioxidant property of resveratrol as proven by
its in vitro/vivo studies(95-97). Different experiments were
conducted on pigs, rats, and even humans from which we
deduced that the risk to peroxidation of biomolecules can be
suppressed by taking resveratrol. However, the mechanism
by which this compound act against different reactive oxygen
intermediates is not clear yet(98).
IV. Anti-Aging Property of Resveratrol
Resveratrol exhibits considerable antiaging effects on
different species such as Caenorhabditis elegans, Drosophila
melanogaster and S. cerevisiae. Moreover, it was observed
that the lifespan of shortlived fish was increased by the
improvement in sirtuin pathways(99-101). This compound also
has the ability to change the physiology of animals (mice)
towards a low-calorie diet, which enhances their endurance
and activeness. Baur et al. proved that reveratrol reduces the
adverse effects of a high calorie diet, decreases insulin-like
growth factor-1 levels and improves the number of mitochondria and motor function(98).
V. Anti-Cancer Property and Mechanisms of Action of Resveratrol against Cancer
Resveratrol possessed excellent cytotoxic features in a
variety of animal models (Table 2). Jang et al. first reported
on the cytotoxic activity of resveratrol and its mechanism
of action(102). They described the application of resveratrol
on mouse skin homing tumor and observed, in each mouse,
98% reduction in the number of skin tumors. Resveratrol
was found to be effective at the initiation, promotion and
progression stages of cancer (Table 3). They also reported
the cyclooxygenase inhibition activity of resveratrol. It is
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Table 2. Anti-cancer activity studies of resveratrol in vitro and in vivo
Model

Dose of resveratrol

Observation

Reference

In vitro studies
SH-SY5Y, NGP and SK-N-AS cells from
human neuroblastoma

50-200 µM resveratrol; Cell
treatment for up to 10 days

Induction of apoptosis via over-expression
of pro-apoptotic factors

van Ginkal et al.(70)

DLD1 and HT29 cells lines from human
colorectal cancer

1-100 µM resveratrol; Also
co-administered with 1 µM
fulvestrant

Over-expression of lysosomal cathepsin
D and caspase activation resulting in the
apoptosis of cancerous cells

Trincheri et al.(106)

Human breast cancer cells (estrogenpositive (MCF-7) and estrogen-negative
(MDA-MB-231))

1 µM resveratrol

Decreased cell proliferation in both types
of cells

Su et al.(113)

S2-013 and CD18 cells from cancerous
pancreas of human

25-100 µM resveratrol;
Dose administration
at 24, 48 and 72 h

Decreased cell proliferation; Significant
effect of duration and dose of treatment

Golka et al.(121)

RPMI 8226 and U266 cell lines in human
multiple myeloma

50 µM resveratrol

Decreased proliferation due to decreased
production of anti-apoptic and
proliferative factors

Bnhardwaj et al.(107)

RPMI 8226, U266, and KM3 cell lines in
human multiple myeloma

50-200 µM resveratrol

Induction of apoptosis; Decrease in cell
proliferation; Cell cycle arrest

Sun et al.(108)

Human colon cancer cells (Etoposide
resistant HT-29

50-400 µM resveratrol

Induction of apoptosis via modulation of
Hwang et al.(111)
adenosine monophosphate kinase signaling
pathways

Human T-cell acute lymphoblastic
leukemia cells (MOLT-4)

16-128 µM resveratrol

Induction of apoptosis via over-expression
of pro-apoptotic factors

Cancerous (estrogen sensitive (LNCaP)
and insensitive (PC-3)) and normal cells
(PZ-HPV-7) From human prostate gland

Cell treatment with
1-150 µM resveratrol
for 12 h to 3 days

Suppression of tumor growth via cell cycle Benitez et al.(110)
arrest, increase in apoptosis, and decrease
in cell proliferation; Significant effect of
duration and Dose of treatment

Human bladder carcinoma (ECV304) cell
lines

1-100 µM resveratrol

Induction of apoptosis via modulation of
Bcl-2 proteins; Significant effect of
duration and dose of treatment

Stocco et al.(118)

2-50 mg/kg of body weight;
administered orally for 35
days

Suppression of tumor growth

Van Ginkel et al.(70)

Lewis lung carcinoma cells grafted to mice 5 or 25 mg/kg of body
weight; administered
intra-peritoneally once
daily for 2 weeks

Decrease in metastasis via suppression of
angiogenesis

Busquets et al.(109)

Breast cancer (MCF-7 and MDA-MB-231) 10 mg/kg of body weight;
cells grafted to female mice
administered orally for
48 h

Tumor suppression in MDA-MB-231 cells
via inactivation of protein kinase B and
modulation of Forkhead proteins

Su et al.(113)

Cecchinato et al.(112)

In vivo studies
Human neuroblastoma (NGP and
SK-N-AS) cells xenografted to mouse

noteworthy that cyclooxygenase is a risk factor for several
cancers. Aggarwal et al., after a series of in vitro experiments
on tumor cell lines, narrated that cell cycle arrest (anti-proliferation) and apoptosis are the modes of anti-tumor activity
of resveratrol(103). Cell cycle arrest could predominantly be
due to the down-regulation of cell cycle proteins(104). Garvin
et al. addressed that resveratrol caused an augmentation
in apoptosis in in vivo tumor models (105). Multiple modes
of apoptosis by resveratrol have been described in literature(72,106-109). Van Ginkel et al., in mouse xenograft models
of human neuroblastoma (SH-SY5Y, NGP and SK-N-AS)
cells, observed that resveratrol (at a concentration of 50 mM)
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provoked the thrashing of mitochondrial membrane potential(70). This polyphenolic compound induced the liberation
of cytochrome C and Smac/Diablo which activated the antecedents (caspase-9 and caspase-3) of the protease-dependent
proapoptotic process(70). Orally administered resveratrol (50
mg/kg body weight/day for 35 days) also suppressed tumor
growth(70). Trincheri et al. also observed the inhibition and
down-regulation of lysosomal cathepsin D during human
colorectal cancer treatment using resveratrol(106). After 48 h
of administering resveratrol (100 mM), the death of human
colorectal cancer cells (DLD1 and HT29) was noted(106).
Benitez et al. narrated the anti-proliferative activity of
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resveratrol at the G0/G1 stage, which subsequently inhibited the cell growth factors in human prostate cancer cell
lines(110). As potential modes of cytotoxicity of resveratrol,
the literature also describes some other pathways of apoptosis like (i) raised levels of pro-apoptotic factors such as
Bax, p21waf, and p53 in the T-cells homing acute lymphoblastic leukemia(111), (ii) diminished levels of anti-apoptotic
factors such as tissue necrosis factor 2, BclxL, Bcl-2, and
cyclin D1(107,110), and (iii) deactivation of anti-apoptotic
factors such as phosphatidylinositol 3′-kinase(112) as well
as the inhibition of serine/threonine protein kinase (STPK)
which in return inhibits the Forkhead proteins (also known as
transcription factors) in in vitro and in vivo cancerous cell of
human breast(113). Forkhead proteins are known to activate
proapoptotic genes resulting in the programmed death of
cells(113). Moreover, Forkhead proteins are also involved in
angiogenesis, the differentiation of cells and DNA repair(114).
Therefore, the mode of cytotoxicity for resveratrol in human
may involve Forkhead protein activation. After exposure
of estrogen-positive as well as estrogen-negative breast
neoplastic cells with resveratrol (10 mg/kg body weight for
48 h), suppression of breast cancer, in vitro and in nude mice,
was observed(113). Busquets et al. reported that resveratrol,
in multiple myeloma cells, could inhibit the nuclear factor
(NF)-κB, which is tumorgenic in nature(109). Resveratrol, in
etoposide-resistant cancer cells, also caused programmed cell
death by activating the adenosine 5′-monophosphate (AMP)
as well as the up-regulation of the protein kinase system. In
addition, the release of reactive oxygen species took place,
which was also responsible for apoptosis by liberating the
cytochrome C from mitochondria. The same mechanism of
action for resveratrol was observed in androgen-insensitive
prostate cancer cells, i.e. (i) increased release of reactive
oxygen species, (ii) inhibition of anti-apoptotic factors, and
(iii) upregulation of pro-apoptotic factors such as TNF(115).
Resveratrol, in a mouse model with prostate cancer,
stimulated the estrogen receptor-b (a tumor suppressor) and
inhibited the growth factors which reduced the proliferation
of cells(116). After administering resveratrol (625 mg/kg of
mouse for 196 days), this polyphenolic compound suppressed
the development of prostate cancer in transgenic adenocarcinoma mice(116). On the other hand, Harper et al. described the
agonistic as well as antagonistic binding of resveratrol with
estrogen receptors, which exhibited that resveratrol induced the
growth of estrogen-dependent human breast cancer cells(116).
Besides this controversy, there are many experimental studies
which described the therapeutic role of resveratrol in breast
cancer(117). Athar et al. evaluated the effectiveness of orally
administered resveratrol in colorectal cancer by treating the
CaCo-2 cells with resveratrol (25 mM) which resulted in
70% growth inhibition(21). Stocco et al. investigated the dosedependent effect of resveratrol on human bladder carcinoma
(ECV304) cell lines during oxidative stress states(118). Higher
doses (>20 µM) of resveratrol induced apoptosis of ECV304
cells via increased pro-apoptotic proteins. Provinciali et al.
elaborated, as a result of food utilization supplemented with
resveratrol, a delayed spontaneous growth of mammary
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tumor in mice and diminished metastasis(119). Similar results
were obtained by La Vecchia and Bosetti, using red wine,
but the consumption of red grapes, in breast cancer, showed
opposite results(120). It has been expressed that the risk of
prostate cancer can be reduced to half by the intake of one
glass of red wine per day. A 60% reduction was observed in
prostate cancer incidence in men consuming four glasses of
red wine a week(120).
In pancreatic and lung melanomas, resveratrol exhibited
antimelanomic activity in vitro and in rat models, through
the inhibition of cell proliferation(121) and retardation of
metastasis(109), respectively. Another report described that
resveratrol (5 and 25 mg/kg of body weight/day for 2 weeks)
prevented metastasis but could not suppress the development
of the tumor in vivo mice lung carcinoma cells(109). This
discrepancy exhibited the specific mode of action of resveratrol through different pathways in various cancer cells. The
anti-proliferative effect of resveratrol (50 mM), alone and in
combination with thalidomide and bortezomib, was studied by
Bhardwaj et al. in human multiple myeloma cancer cell lines
U266 (ATCC TIB-196) and RPMI 8226 (ATCC CCL-155)
which were the plasmacytomas of B-cell origin(107).
Sexton et al. studied the anti-tumor activity of resveratrol
in high dose against uterine cancer cells(122). They described
its mode of action that involved the expression of cyclooxygenase as well as other enzymes which are engaged in prostaglandin synthesis. Harikumar et al. investigated the anticancer activity of resveratrol (characteristically multitargeted
and safe) in combination with gemcitabine (standard drug for
pancreatic cancer which is not very efficaceous alone) using
the pancreatic cancer xenografts in nude mice(123). The antiproliferative activity of resveratrol as well as the apoptotic
activity of gemcitabine synergistically suppressed the constitutive activation of NF-κB and expression of carcinogen
factors such as bcl-2, bcl-xL, cyclooxygenase-2, cyclin D1
matrix metallopeptidase-9 and vascular endothelial growth
factor, resulting in the potentiation of anti-cancer effect of
gemcitabine(123). Wu et al. and Bernhaus et al. elaborated on
the synergistic effect of resveratrol with 5-fluorouracil(124)
and gemcitabine(125), respectively.

Table 3. Modes of anti-cancer activity of resveratrol(102,103,109)
No.

Modes of anticancer activity of reveratrol

1

Induction of apoptosis of transformed cells

2

Cell cycle arrest

3

Suppression of angiogenesis

4

Inhibition of invasion and metastasis

5

Sensitizing cancerous cells for chemotherapy induced
apoptosis

6

Phase I enzyme inhibition, thus blockage of carcinogen
activation

7

Activation of phase II carcinogen detoxifying enzymes via
increased anti-oxidant activity

8

Modulation of Forhead proteins
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VI. Approaches to Enhance Resveratrol Bioavailability
Water solubility, membrane permeability and metabolism
of micromolecular drugs play an important role in their oral
bioavailability(126,127). Numerous attempts on enhancing the
bioavailability of resveratrol have been documented(126-142).
To stabilize and protect resveratrol, this highly photosensitive drug had been effectively formulated as monodisperse
functionalized porous polymeric microspheres(128). Another
researcher successfully employed saccharomyces cerevisiae as
an encapsulating wall material to prepare yeast-encapsulated
resveratrol(129). To improve the water solubility of resveratrol,
various techniques such as the preparation of complexes with
β-cyclodextrins(130-133), nanoemulsion(134) and micellar solutions(135) have been successfully used. Some studies involved
the development of sustained release and targeted release
formulations such as resveratrol-loaded Ca-pectinate beads
and Zn-pectinate, microparticles, double-layered ultrafine
fibers using polycaprolactone and resveratrol as the outer and
inner layers, β-cyclodextrin nanosponges, acoustically active
lipospheres, lipid-core nanocapsules, solid lipid nanoparticles,
resveratrol incorporated in liposomes, biodegradable nanoparticles and emulsion–liposome blends and emulsions.
Pterostilbene (3′,5′-dimethoxy-4′-hydroxy-trans-stilbene),
a natural analog of resveratrol, was studied in healthy rats to
compare its absolute and relative bioavailabilities to those
of resveratrol after single equimolar i.v. doses (resveratrol
10 mg/kg and pterostilbene 11.2 mg/kg) as well as repeated
oral administration for 14 days (resveratrol 50 - 150 mg/kg/d
and pterostilbene 56 - 168 mg/kg/d). It resulted in a three- to
four-times increased bioavailability and total plasma levels
of both the parent compound and its metabolites for pterostilbene in comparison with resveratrol(138).
Youn et al. reported that piceatannol (3′,5′,3′,4′-tetrahydroxy-trans-stilbene), one of the metabolites of resveratrol
produced by the action of cytochrome P450 enzyme CYP1B1
on resveratrol, appreciably inhibited experimentally-induced
inflammatory injury as well as over-expressed the iNOS in a
similar fashion as resveratrol did in mouse colitis(139).
In future, there will be many other opportunities for
augmenting resveratrol bioavailablility, such as by inhibiting
resveratrol metabolism and prolonging its availability in
blood, screening of resveratrol metabolites for their potential
bioactivities, synthesizing and consuming of readily bioavailable resveratrol analogs, and applying nanotechnology in
resveratrol delivery system development(136). Johnson et al.
co-administered resveratrol with piperine, an alkaloid derived
from black pepper, in vivo for the inhibition of glucuronidation in healthy mice(137). This study reported an increase in the
maximum level of serum resveratrol, the area under the resveratrol concentration curve, and the time to reach maximum
level of serum resveratrol by 1544, 229 and 100% after a
single oral administration. In current clinical studies, only
conventional dosage forms like tablets and capsules(140,141)
are evaluated to assess resveratrol bioavailability in humans.
Presently, resveratrol-loaded novel drug delivery systems like
micro- and nanoparticles are also being studied(141,142).
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CONCLUSIONS
Red wine contains many bioactive compounds including
resveratrol (0.38 mg/mL of red wine) which can potentially
act as anti-oxidant, anti-aging and anti-cancer agents. There
are multiple sources and processing techniques for the
preparation of wine, due to which this supplementary diet
possesses different phytochemicals in various concentrations. The health-promoting features of resveratrol are now
apparent. Many research papers are available in literature
which described the pharmacokinetics, bioavailability and
potential anti-tumor activities of this polyphenol and its
mode of cytoprotective effect. These research investigations provided a direction to further explore this emerging
therapeutic agent in cancer therapy. However, the research
to disclose its chemopreventive effects is in its initial stage
and further studies are needed to determine the amount of
red wine or resveratrol that should be ingested in 24 h for
the protection of an individual against cancers, the type of
food that should be avoided or taken in parallel with the
consumption of red wine or other resveratrol supplements to
resolve bioavailability issues, and the level of activities of
the metabolites of resveratrol. There are many other limitations in these studies, including the need for quality dosage
forms, variable study designs, lack of information on disease
progression and tumor recurrence, short period studies, and
small sample sizes. Therefore, it is impracticable to extract
unambiguous conclusions on the clinical value of resveratrol
in cancer patients. Phase I clinical studies on healthy people
are in progress to achieve specific goals like (i) the determination of levels of resveratrol and its metabolites in plasma and
excretions, (ii) dose adjustment, and (iii) toxicity studies of
resveratrol. Future studies can be focused on the bioavailability enhancement of resveratrol and possible anti-cancer
activities of its metabolites as they are found in considerable
quantities in biofluids. In addition, other dietary sources of
resveratrol like peanuts and berries should also be investigated as potential anticancer therapies. Finally, the future
for effective resveratrol delivery depends on the development of novel formulation strategies to augment resveratrol
bioavailability.
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